Ecor1 Capital, Llc Sells 456,000 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGRGet Rating) major shareholder Ecor1 Capital, Llc sold 456,000 shares of Voyager Therapeutics stock in a transaction on Monday, January 9th. The shares were sold at an average price of $7.67, for a total value of $3,497,520.00. Following the transaction, the insider now owns 4,297,907 shares in the company, valued at approximately $32,964,946.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Ecor1 Capital, Llc also recently made the following trade(s):

  • On Wednesday, January 11th, Ecor1 Capital, Llc sold 110,000 shares of Voyager Therapeutics stock. The shares were sold at an average price of $8.50, for a total value of $935,000.00.

Voyager Therapeutics Price Performance

Shares of NASDAQ VYGR opened at $9.29 on Friday. The business’s 50-day moving average price is $5.93 and its two-hundred day moving average price is $6.11. Voyager Therapeutics, Inc. has a one year low of $2.60 and a one year high of $10.60. The company has a market capitalization of $358.66 million, a P/E ratio of -20.20 and a beta of 0.93.

Institutional Trading of Voyager Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Armistice Capital LLC lifted its position in shares of Voyager Therapeutics by 32.4% in the third quarter. Armistice Capital LLC now owns 3,396,000 shares of the company’s stock worth $20,104,000 after buying an additional 832,000 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Voyager Therapeutics by 1.9% in the third quarter. Price T Rowe Associates Inc. MD now owns 843,711 shares of the company’s stock worth $4,996,000 after buying an additional 15,761 shares during the last quarter. Millennium Management LLC lifted its position in shares of Voyager Therapeutics by 291.0% in the second quarter. Millennium Management LLC now owns 828,796 shares of the company’s stock worth $4,898,000 after buying an additional 616,814 shares during the last quarter. BlackRock Inc. lifted its position in shares of Voyager Therapeutics by 4.7% during the 3rd quarter. BlackRock Inc. now owns 590,504 shares of the company’s stock worth $3,496,000 after purchasing an additional 26,289 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in shares of Voyager Therapeutics during the 3rd quarter worth about $1,713,000. Institutional investors and hedge funds own 59.58% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, November 14th.

About Voyager Therapeutics

(Get Rating)

Voyager Therapeutics, Inc, a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy.

Featured Articles

Insider Buying and Selling by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.